Now screening · Retatrutide study

The next chapter of weight health is being written by people like you.

Retatrutide is an investigational once-weekly medicine that activates three metabolic receptors at once. In a phase 2 trial, the highest dose produced an average body-weight reduction of 24.2%. It is not approved yet — and the research deciding its future is screening participants now.

Takes about three minutes · No cost, no obligation

Check my eligibility

Three minutes. No cost, no obligation.

A study coordinator will call you here.

The science · Triple agonist

Most weight medicines act on two receptors. This one acts on three.

Retatrutide (LY3437943) is a single molecule engineered to activate GLP-1, GIP and glucagon receptors together. The first two are familiar from existing weight medications. The third — glucagon — is the part researchers believe may add something the others cannot: more energy spent, rather than only less taken in.

01

GLP-1

Quiets appetite

Signals fullness to the brain and slows how quickly the stomach empties, so meals satisfy sooner and grazing fades.

02

GIP

Improves fuel handling

Influences the insulin response and how the body stores and uses fat — helping energy go where it is needed.

03

GLUCAGON

Raises energy burn

Increases calorie expenditure and works on stored fat, including the visceral fat wrapped around organs.

This is how researchers currently understand the mechanism. Retatrutide is investigational and has not been approved by the FDA or any other regulatory agency.

The research so far

People reach for the word “miracle.” The data says something better: it’s real.

A 2023 phase 2 trial published in The New England Journal of Medicine randomized 338 adults with obesity to weekly retatrutide or placebo. At 48 weeks, average weight loss climbed with each dose level — reaching 24.2% at the highest dose studied.

Participants also saw improvements in waist circumference, blood pressure and triglycerides, markers that matter for long-term metabolic and heart health.

Results describe group averages, not a promise for any one person. Phase 3 trials are underway to confirm safety and effectiveness.

338

adults with obesity randomized to weekly retatrutide or placebo

48 wks

of follow-up, with weight loss rising at each dose level

3 markers

also improved: waist circumference, blood pressure, triglycerides

How it works

Four unhurried steps, from curiosity to clarity.

1

Apply in three minutes

Answer a few short questions about your health and goals. No cost, no commitment.

2

A coordinator calls

A study coordinator walks you through what participation involves and answers your questions.

3

A screening visit

A licensed clinic confirms whether you qualify, with exams and labs at no cost to you.

4

Begin — or step away

Enroll if it feels right. You can leave a study at any time, for any reason.

Eligibility

Who these studies are looking for

YOU MAY QUALIFY IF

  • You are 18 or older
  • Your BMI is 30 or higher, or 27 or higher with a weight-related health condition
  • You have tried diet and exercise and want to explore a clinical option
  • You can attend study visits at a nearby clinical site

LIKELY NOT A FIT

  • You are pregnant, nursing or planning pregnancy
  • You have a history of pancreatitis
  • You have a personal or family history of medullary thyroid cancer
  • You are currently taking another weight-loss medication

Every study sets its own criteria. A coordinator will confirm what applies to you.

The point was never the number on the scale.

Care without a bill

Study-related visits, exams, labs and the study medication are provided at no cost to participants.

Supervision, not a subscription

Licensed physicians monitor your health throughout the study, with nothing to renew and nothing to cancel.

Paid for your time

Participants receive reimbursement for their time and travel to study visits.

A stake in what comes next

Your participation helps answer whether this medicine is safe and effective for the people who may need it.

Questions, answered

Honest about the trade-offs.

Clinical research asks something of you. Here is what to weigh before you decide.

Is retatrutide approved by the FDA?
No. Retatrutide is investigational and has not been approved by the FDA or any other regulatory agency. Clinical trials are how its safety and effectiveness are being evaluated.
Will I actually receive retatrutide?
Not necessarily. Many trials are randomized and placebo-controlled, so some participants receive a placebo. The study team will explain exactly how assignment works before you enroll.
Does participating cost anything?
No. Study-related care is provided at no cost, and participants are reimbursed for their time and travel.
What are the possible side effects?
In earlier trials, the most commonly reported effects were gastrointestinal, such as nausea, diarrhea, vomiting and constipation. Other risks may be unknown. The study doctor will review all known risks with you.
Can I leave a study once I start?
Yes. Participation is voluntary and you may step away at any time, for any reason.

Apply to be screened

Find out if you may qualify.

Tell us a little about yourself. If a nearby study might be a fit, a coordinator will call to explain everything — no cost, no obligation.

✓ Takes about three minutes
✓ Free to apply
✓ Leave at any time
Back to the form

Questions first? Write to hello@medreta.com

24.2%

Average body-weight reduction at 48 weeks in the highest-dose group

Phase 2 trial · 12 mg arm · Adults with obesity

✓ Study care at no cost

✓ Physician-supervised

✓ Reimbursement for time & travel

✓ Step away at any time

MedReta connects adults interested in retatrutide research with licensed clinical trial sites. Retatrutide is an investigational drug that has not been approved by the FDA or any other regulatory agency. Results from past studies describe group averages and do not predict individual outcomes. Participation is voluntary.

© 2026 MedReta. All rights reserved.